It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The coronavirus pandemic has thrown a spotlight on messenger RNA (mRNA)—the molecule that carries a cell’s instructions for making proteins. Hundreds of millions of people worldwideExit Disclaimer have received mRNA vaccines that provide powerful protection against severe COVID-19 caused by infection with SARS-CoV-2.
As stunningly successful as the mRNA COVID-19 vaccines have been, researchers have long hoped to use mRNA vaccines for a very different purpose—to treat cancer. mRNA-based cancer treatment vaccines have been tested in small trials for nearly a decade, with some promising early results.
In fact, scientists at both Pfizer-BioNTech and Moderna drew on their experience developing mRNA cancer vaccines to create their coronavirus vaccines. Now, some investigators believe the success of the mRNA COVID-19 vaccines could help accelerate clinical research on mRNA vaccines to treat cancer.
When the pandemic struck, mRNA vaccine technology had an unexpected opportunity to demonstrate its promise, said Norbert Pardi, Ph.D., of the University of Pennsylvania Perelman School of Medicine, whose research focuses on mRNA-based vaccines.
As cancer researchers pursue these questions, other investigators will be developing knowledge from the growing number of people around the world who are receiving mRNA coronavirus vaccines.
Unfortunately, it took a pandemic for there to be broad acceptance of mRNA vaccines among the scientific community,” she added. “But the global use of COVID-19 mRNA vaccines has demonstrated the safety of this approach and will open doors for cancer vaccines.
originally posted by: just4fun
a reply to: duncanhidao
So super AIDS ... Great.
Its not a movie its a South Park episode
originally posted by: SMOKINGGUN2012
a reply to: PioneerFigureSkating
Well obviously I told YOU no matter who you were asking....FWIW...feel free to ONLY trust that poster....
Moderna and Excision BioTherapeutics are stepping into a battle with HIV, a 41-year epidemic that has confuddled drug developers and vaccine makers the world over.
The COVID-19 vaccine maker has started applying its mRNA technology to deliver a jab for HIV on the same day Excision says it’s begun investigating a CRISPR-based therapy for the immune-system attacking virus.
The companies are attempting to upend the landscape for fighting HIV, as currently approved treatments, known as antiretroviral therapies, reduce the viral load to levels that can’t spread to others, but the meds must be taken daily for life and the virus lives on hidden in the genome of T cells.
For its part, Moderna is helping nonprofit scientific research group IAVI deliver HIV vaccine antigens using the COVID-19 vaccine maker’s messenger RNA technology. The phase 1 trial, dubbed IAVI G002, is testing whether delivering priming and boosting HIV immunogens can spark certain B-cell responses and lead them to mature into broadly neutralizing antibodies. IAVI and Scripps Research created the immunogens, and the Bill & Melinda Gates Foundation is fronting the bill for the trial.
Abstract
Over the past decade, the global scientific community have begun to recognize the unmatched value of an extraordinary drug, ivermectin, that originates from a single microbe unearthed from soil in Japan. Work on ivermectin has seen its discoverer, Satoshi Ōmura, of Tokyo’s prestigious Kitasato Institute, receive the 2014 Gairdner Global Health Award and the 2015 Nobel Prize in Physiology or Medicine, which he shared with a collaborating partner in the discovery and development of the drug, William Campbell of Merck & Co. Incorporated. Today, ivermectin is continuing to surprise and excite scientists, offering more and more promise to help improve global public health by treating a diverse range of diseases, with its unexpected potential as an antibacterial, antiviral and anti-cancer agent being particularly extraordinary.
Putin and Xi could sign 15 agreements, Kremlin aide Yuri Ushakov said, adding those deals might cover energy, which is already an area of close cooperation between oil and gas exporter Russia and the world's top energy consumer China.
China and Russia both say they want to increase the global role of their currencies and reduce reliance on the U.S. dollar. China has been using its Belt and Road Initiative to promote trade in the yuan and has signed local currency swap agreements with many participating countries, including Russia.
Russia added the yuan to a list of reserve currencies in 2015 and, as of 2021, about 13% of its international reserves were held in the Chinese currency. Russia's total reserves now stand at $640 billion. In 2021, Russia added the yuan to its National Wealth Fund (NWF), a part of state reserves, saying it needed to diversify its savings.
Both China and Russia have also been developing alternatives to SWIFT, the international payment network. Beijing has been encouraging the use of its homegrown alternative, known as the CIPS clearing and settlement services system. Moscow has set up its own banking messaging system, known as SPFS.
The 12 Russian banks taking part in the first phase of the Central Bank of Russia’s digital ruble pilot scheme have started or are ready to start trialling the central bank digital currency (CBDC) across a range of payment types.
Hey steak, how much do you cost?
Too much for you, deplorable ...